{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3596, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": "The slide features both the Aeglea and Spyre Therapeutics logos, indicating a transition or merger context.", "imagePath": "https://imgproxy.kitesheet.com/fP2olevAOiGWuUVMRCp3PoNbSJbJ1aD8XjWdfm_EIas/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ZTZmNmZmYjFhN2VjYjI3ODI3NmRjYmQ2OGJkMWQ3Ny9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/1", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/HB4acLJv_1BiYcX91ggomBM30UwTP6A_iC2iW1GcPHs/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ZTZmNmZmYjFhN2VjYjI3ODI3NmRjYmQ2OGJkMWQ3Ny9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/71_PhsMWZPClbkArUuf2AjuMEdP5jJmQnoeL1FfcG6c/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ZTZmNmZmYjFhN2VjYjI3ODI3NmRjYmQ2OGJkMWQ3Ny9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/o-WpA0ta3n_vTu5N7a9ACi5GzpT_1_eFjW8r2iTBZS4/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ZTZmNmZmYjFhN2VjYjI3ODI3NmRjYmQ2OGJkMWQ3Ny9wMDAxLnBuZw" }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "appendix_disclosure", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/2", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "other", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/3", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "appendix_data", "function": "analyze_data", "notes": "Includes a footnote regarding a 1-for-25 reverse stock split.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/4", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a pipeline chart format to show the development status of seven different programs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/5", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-5", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "market_sizing", "function": "size_opportunity", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/6", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-6", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a donut chart to illustrate market growth from 2021 to 2028.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/7", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-7", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "problem_statement", "function": "frame_problem", "notes": "The chart uses a visual metaphor of an arrow pointing from current standard of care (SOC) to a higher efficacy/convenience target.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/8", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-8", "loopMatches": [], "arcBeatMatches": [ { "to": 8, "from": 8, "beatId": "7af050bc-2753-4f31-9805-17415e57f291", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem (Identify pain)", "beatSlug": "problem-agitate-solution-problem-identify-pain", "evidence": "The document identifies the limitations of current biologics and the need for new approaches.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 15, "from": 8, "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "key_messages", "function": "present_framework", "notes": "The slide uses a numbered list format to present strategic pillars.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/9", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 15, "from": 8, "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a visual representation of an antibody molecule with callouts to specific engineering improvements, supported by a scatter plot showing clinical precedent for half-life extension.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/10", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-10", "loopMatches": [ { "to": 19, "from": 10, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d", "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.", "position": 0, "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.7, "description": "Establish a tension, present data, then deliver the insight that changes everything" } ], "arcBeatMatches": [ { "to": 15, "from": 8, "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" }, { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "why_now", "function": "cite_precedent", "notes": "Uses a visual metaphor of antibody combination to explain the therapeutic strategy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/11", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-11", "loopMatches": [ { "to": 19, "from": 10, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d", "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.", "position": 0, "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.7, "description": "Establish a tension, present data, then deliver the insight that changes everything" }, { "to": 11, "from": 11, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "8e9697fd-79aa-4fe8-a218-0ec6e1bba9da", "evidence": "The document highlights the growing market and the need for improved solutions.", "position": 1, "objective": "Why now is the right time for Spyre's IBD treatment solutions?", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [ { "to": 15, "from": 8, "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" }, { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "solution", "function": "cite_precedent", "notes": "The slide uses a Venn diagram to represent the intersection of genetic targets and a bar chart to demonstrate the efficacy of patient selection.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/12", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-12", "loopMatches": [ { "to": 19, "from": 10, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d", "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.", "position": 0, "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.7, "description": "Establish a tension, present data, then deliver the insight that changes everything" } ], "arcBeatMatches": [ { "to": 15, "from": 8, "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" }, { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a Gantt-style pipeline visualization to show progress of seven distinct programs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/13", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-13", "loopMatches": [ { "to": 19, "from": 10, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d", "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.", "position": 0, "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.7, "description": "Establish a tension, present data, then deliver the insight that changes everything" } ], "arcBeatMatches": [ { "to": 15, "from": 8, "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" }, { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a Gantt-style layout to show progress across Discovery, IND-Enabling, and Clinical stages.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/14", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-14", "loopMatches": [ { "to": 19, "from": 10, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d", "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.", "position": 0, "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.7, "description": "Establish a tension, present data, then deliver the insight that changes everything" } ], "arcBeatMatches": [ { "to": 15, "from": 8, "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" }, { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "traction", "function": "show_traction", "notes": "Includes a KOL quote and two charts: a bar chart for global sales and a line chart for market share.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/15", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-15", "loopMatches": [ { "to": 19, "from": 10, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d", "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.", "position": 0, "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.7, "description": "Establish a tension, present data, then deliver the insight that changes everything" } ], "arcBeatMatches": [ { "to": 15, "from": 8, "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" }, { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The chart uses a vertical axis to imply a safety spectrum (Safest to Riskiest) and a horizontal axis for efficacy (clinical remission %).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/16", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-16", "loopMatches": [ { "to": 19, "from": 10, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d", "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.", "position": 0, "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.7, "description": "Establish a tension, present data, then deliver the insight that changes everything" } ], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a checkmark/arrow matrix to highlight competitive differentiation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/17", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-17", "loopMatches": [ { "to": 19, "from": 10, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d", "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.", "position": 0, "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.7, "description": "Establish a tension, present data, then deliver the insight that changes everything" } ], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a standard antibody diagram to annotate specific engineering improvements.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/18", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-18", "loopMatches": [ { "to": 19, "from": 10, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d", "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.", "position": 0, "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.7, "description": "Establish a tension, present data, then deliver the insight that changes everything" } ], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "solution", "function": "present_solution", "notes": "Includes structural visualization of the epitope and two dose-response curves.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/19", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-19", "loopMatches": [ { "to": 19, "from": 10, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d", "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.", "position": 0, "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.7, "description": "Establish a tension, present data, then deliver the insight that changes everything" } ], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "traction", "function": "analyze_data", "notes": "The chart shows dose-response curves for three donors; the table summarizes the calculated EC50 values.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/20", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-20", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "traction", "function": "show_traction", "notes": "The chart uses a log-linear scale for concentration over time to demonstrate the beta-elimination phase.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/21", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-21", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a bar chart to compare pharmacokinetic properties between a proprietary drug candidate (SPY001) and a competitor (Entyvio).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/22", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-22", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "comparison_table", "function": "compare_peers", "notes": "Uses a visual timeline/comparison to contrast current standard of care with the proposed product.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/23", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-23", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a bar chart to show benchmark data alongside a specific exposure-response analysis for vedolizumab.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/24", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-24", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "appendix_data", "function": "analyze_data", "notes": "Data from GEMINI 1 study; highlights that higher exposure does not necessarily correlate with higher remission rates.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/25", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-25", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a 2x2 grid to summarize the program's value proposition.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/26", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-26", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The slide uses peer benchmarking to justify valuation growth expectations based on clinical trial phases.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/27", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-27", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "comparison_table", "function": "compare_peers", "notes": "The table highlights the competitive positioning of SPY001, specifically emphasizing its subcutaneous administration profile.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/28", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-28", "loopMatches": [ { "to": 28, "from": 28, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "97dc64e0-9ee7-4111-9a96-eee5c2c2a6af", "evidence": "The document presents Spyre's plan to rapidly advance combination programs.", "position": 2, "objective": "What if Spyre's combination programs could create optimal combinations in IBD?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "testimonial", "function": "cite_precedent", "notes": "The chart compares preference share between Naïve and Switch patients for four different drug profiles.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/29", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-29", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a Gantt-style pipeline visualization to show progress from discovery to clinical stages for seven distinct programs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/30", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-30", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The chart uses a color-coded safety gradient on the Y-axis and efficacy percentages on the X-axis.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/31", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-31", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a checkmark-based comparison matrix to highlight SPY002's superior profile.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/32", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-32", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "solution", "function": "present_solution", "notes": "The slide uses an antibody diagram to annotate specific technical improvements (half-life extension and formulation).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/33", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-33", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a cross-trial comparison to argue that the superiority of one mechanism over the other is not yet established, supporting a redundant development strategy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/34", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-34", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "product_demo", "function": "present_solution", "notes": "The slide uses two distinct chart types: a dose-response curve (sigmoidal) and a scatter plot to demonstrate potency and specificity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/35", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-35", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a 2x2 grid to summarize the program's value proposition.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/36", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-36", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a mountain-like diagram to represent sequential or cumulative expansion of indications.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/37", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-37", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a Gantt-style visualization to show the progression of various IBD programs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/38", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-38", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a biological process diagram to illustrate the mechanism of action for three distinct drug candidates.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/39", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-39", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 40, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a bar chart to illustrate the additive effect of combining two therapies, with a supporting table for N, maintenance remission, and safety.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/40", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-40", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a comparison framework to highlight the competitive advantage of Spyre's gut-selective approach.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/41", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-41", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 42, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a process flow diagram to illustrate the clinical trial strategy for SPY001 and SPY003.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/42", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-42", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 43, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a visual representation of a bispecific or combination antibody structure.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/43", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-43", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 44, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a Venn diagram to show target overlap and a hierarchical tree diagram to show diagnostic-driven treatment selection.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/44", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-44", "loopMatches": [], "arcBeatMatches": [ { "to": 44, "from": 10, "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 45, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a comparative bar chart structure to validate the efficacy of genetic companion diagnostics (CDx) in improving clinical outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/45", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-45", "loopMatches": [], "arcBeatMatches": [ { "to": 56, "from": 45, "beatId": "a269a747-0743-41c8-a64a-96220e98956c", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 46, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/46", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-46", "loopMatches": [], "arcBeatMatches": [ { "to": 56, "from": 45, "beatId": "a269a747-0743-41c8-a64a-96220e98956c", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 47, "slideType": "team_bio", "function": "other", "notes": "The slide includes a section for Management team and a section for Board of Directors, with headshots and titles for each individual, followed by a logo grid of affiliated organizations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/47", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-47", "loopMatches": [], "arcBeatMatches": [ { "to": 56, "from": 45, "beatId": "a269a747-0743-41c8-a64a-96220e98956c", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 48, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a table-based timeline structure to map drug candidates (SPY001-004) against expected clinical milestones.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/48", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-48", "loopMatches": [], "arcBeatMatches": [ { "to": 56, "from": 45, "beatId": "a269a747-0743-41c8-a64a-96220e98956c", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 49, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The slide uses a custom bar chart visualization within a table to show market cap ranges (Min, IPO, Today, Max).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/49", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-49", "loopMatches": [], "arcBeatMatches": [ { "to": 56, "from": 45, "beatId": "a269a747-0743-41c8-a64a-96220e98956c", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 50, "slideType": "comparison_table", "function": "compare_peers", "notes": "The table maps historical M&A deal values to Spyre's internal pipeline milestones.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/50", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-50", "loopMatches": [], "arcBeatMatches": [ { "to": 56, "from": 45, "beatId": "a269a747-0743-41c8-a64a-96220e98956c", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 51, "slideType": "closing_ask", "function": "state_next_steps", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/51", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-51", "loopMatches": [], "arcBeatMatches": [ { "to": 56, "from": 45, "beatId": "a269a747-0743-41c8-a64a-96220e98956c", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 52, "slideType": "team_bio", "function": "other", "notes": "The slide highlights the partnership with Paragon Therapeutics, detailing its founding, team size, operational capacity, program count, and the spin-out of Apogee Therapeutics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/52", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-52", "loopMatches": [], "arcBeatMatches": [ { "to": 56, "from": 45, "beatId": "a269a747-0743-41c8-a64a-96220e98956c", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 53, "slideType": "unfair_advantage", "function": "present_solution", "notes": "The slide uses a series of icons to represent different scientific methodologies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/53", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-53", "loopMatches": [], "arcBeatMatches": [ { "to": 56, "from": 45, "beatId": "a269a747-0743-41c8-a64a-96220e98956c", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d132-769f-97bd-4a840dd24899", "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 54, "slideType": "solution", "function": "present_solution", "notes": "The central graphic is an antibody structure inside a pentagon, representing the five optimization pillars.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/54", "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899", "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-54", "loopMatches": [], "arcBeatMatches": [ { "to": 56, "from": 45, "beatId": "a269a747-0743-41c8-a64a-96220e98956c", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d059-759d-8e0a-99644712d3dd", "docSlug": "f911cd737b9fddb4d5979d6a089cb4fc", "documentTitle": "Yatsen | Results Presentation Deck | 17 slides", "authorId": "yatsen", "authorName": "Yatsen Holding Limited", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d059-759d-8e0a-99644712d3dd/12", "deckHref": "/decks/019de075-d059-759d-8e0a-99644712d3dd", "deckAnchorHref": "/decks/019de075-d059-759d-8e0a-99644712d3dd#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 11, "beatId": "aa480793-8ee0-43e2-9340-77e91bbf94c9", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The presentation concludes with a financial review and a thank you note.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d059-759d-8e0a-99644712d3dd", "docSlug": "f911cd737b9fddb4d5979d6a089cb4fc", "documentTitle": "Yatsen | Results Presentation Deck | 17 slides", "authorId": "yatsen", "authorName": "Yatsen Holding Limited", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide explains the drivers behind the financial performance metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d059-759d-8e0a-99644712d3dd/13", "deckHref": "/decks/019de075-d059-759d-8e0a-99644712d3dd", "deckAnchorHref": "/decks/019de075-d059-759d-8e0a-99644712d3dd#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 11, "beatId": "aa480793-8ee0-43e2-9340-77e91bbf94c9", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The presentation concludes with a financial review and a thank you note.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d059-759d-8e0a-99644712d3dd", "docSlug": "f911cd737b9fddb4d5979d6a089cb4fc", "documentTitle": "Yatsen | Results Presentation Deck | 17 slides", "authorId": "yatsen", "authorName": "Yatsen Holding Limited", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The chart shows a breakdown of R&D, G&A, S&M, and Fulfillment expenses.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d059-759d-8e0a-99644712d3dd/14", "deckHref": "/decks/019de075-d059-759d-8e0a-99644712d3dd", "deckAnchorHref": "/decks/019de075-d059-759d-8e0a-99644712d3dd#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 11, "beatId": "aa480793-8ee0-43e2-9340-77e91bbf94c9", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The presentation concludes with a financial review and a thank you note.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d059-759d-8e0a-99644712d3dd", "docSlug": "f911cd737b9fddb4d5979d6a089cb4fc", "documentTitle": "Yatsen | Results Presentation Deck | 17 slides", "authorId": "yatsen", "authorName": "Yatsen Holding Limited", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide provides a detailed breakdown of adjustments made to GAAP net income to arrive at non-GAAP figures, including share-based compensation, amortization, and investment revaluations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d059-759d-8e0a-99644712d3dd/15", "deckHref": "/decks/019de075-d059-759d-8e0a-99644712d3dd", "deckAnchorHref": "/decks/019de075-d059-759d-8e0a-99644712d3dd#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 11, "beatId": "aa480793-8ee0-43e2-9340-77e91bbf94c9", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The presentation concludes with a financial review and a thank you note.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d059-759d-8e0a-99644712d3dd", "docSlug": "f911cd737b9fddb4d5979d6a089cb4fc", "documentTitle": "Yatsen | Results Presentation Deck | 17 slides", "authorId": "yatsen", "authorName": "Yatsen Holding Limited", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The chart displays two distinct metrics: a running balance (top row) and quarterly cashflow (bars).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d059-759d-8e0a-99644712d3dd/16", "deckHref": "/decks/019de075-d059-759d-8e0a-99644712d3dd", "deckAnchorHref": "/decks/019de075-d059-759d-8e0a-99644712d3dd#slide-16", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 11, "beatId": "aa480793-8ee0-43e2-9340-77e91bbf94c9", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The presentation concludes with a financial review and a thank you note.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d059-759d-8e0a-99644712d3dd", "docSlug": "f911cd737b9fddb4d5979d6a089cb4fc", "documentTitle": "Yatsen | Results Presentation Deck | 17 slides", "authorId": "yatsen", "authorName": "Yatsen Holding Limited", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "closing_ask", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d059-759d-8e0a-99644712d3dd/17", "deckHref": "/decks/019de075-d059-759d-8e0a-99644712d3dd", "deckAnchorHref": "/decks/019de075-d059-759d-8e0a-99644712d3dd#slide-17", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 11, "beatId": "aa480793-8ee0-43e2-9340-77e91bbf94c9", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The presentation concludes with a financial review and a thank you note.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }